,,ii #aahth ,,congress #ast ,session ,s4 #aebb ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,may #aj1 #bjbc,mr4 ,marshall introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to require the ,secretary of ,health and ,human ,services to conduct a study on the designation of biosimilar biological products as interchangeable4 #a4 ,study on the substitution of interchangeable biological products 7a7 ,report on biosimilar biological product interchangeability ,not later than #d years after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services 7referred to in this section as the ,secretary71 acting through the ,commissioner of ,food and ,drugs1 shall submit to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives a report on the designation of biosimilar biological products as interchangeable1 under section #cea7k77#d7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k77#d774 ,such report shall-- 7#a7 describe any challenges faced by manufacturers in developing and obtaining approval under section #cea7k7 of such ,act for biosimilar biological products that receive such interchangeability designation2 7#b7 summarize the experience of the ,food and ,drug ,administration in reviewing applications for biosimilar biological products that seek an interchangeability designation1 including compared to applications for biosimilar biological products under such section #cea7k7 that do not seek such designation2 7#c7 summarize1 at a high level1 the data and information that the ,food and ,drug ,administration has reviewed to support applications for interchangeability under section #cea7k77#d7 of such ,act1 including data from switching studies1 and the differences between the findings from such data and information compared to the data and information that the ,food and ,drug ,administration has reviewed for biosimilar biological products that have not received a designation of interchangeability2 7#d7 describe the existing authority of the ,food and ,drug ,administration to determine1 on a case-by-case basis1 the evidence needed to support an interchangeability designation1 and how the ,food and ,drug ,administration has used such authority1 including the factors that the agency may consider when making those judgements2 7#e7 describe how the ,food and ,drug ,administration has considered real-world evidence or other data and information1 including from use of the biological product in other countries1 in determining whether a biosimilar biological product meets the criteria for the interchangeability designation2 7#f7 describe the differences between the regulatory and scientific considerations for determining a biological product to be interchangeable under section #cea7k77#d7 of such ,act 7#db ,u4,s4,c4 #bfb7k77#d77 and the system for assigning therapeutic equivalence ratings to drugs approved under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee72 and 7#g7 assess the uptake of biosimilar biological products1 and the impact of the efforts of the ,food and ,drug ,administration to improve adoption of biosimilar biological products through multimedia education and curriculum materials4 7b7 ,stakeholder input ,for purposes of developing the report described in subsection 7a71 the ,secretary may convene workshops or listening sessions1 establish dockets to receive public comment1 or use other means to obtain input from interested stakeholders4 7c7 ,information disclosure ,nothing in this section shall be construed to authorize the disclosure of information that is prohibited from disclosure under section #cja7;j7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cca7;j77 or section #aije of title #ah1 ,united ,states ,code1 or subject to withholding under paragraph 7#d7 of section #eeb7;b7 of title #e1 ,united ,states ,code 7commonly referred to as the ,freedom of ,information ,act74